Summary
The purpose of these studies was to determine whether macrophages of mice pretreated with the chemotherapeutic agent adriamycin (ADR) could be systemically activated by IV injection of liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE), a lipophilic derivative of muramyl dipeptide. Lower than normal levels of alveolar macrophages or peritoneal exudate macrophages were found in mice following IV injection of ADR. This decrease was dose-dependent and, in mice given <10 mg ADR/kg, it was transient (14 days). Peritoneal macrophages surviving the administration of 15 mg ADR/kg were tumoricidal.
At various times after single or repeated administration of ADR, mice were given IV or IP injections of liposomes containing MTP-PE. One day thereafter, the cytotoxic activity of the in situ-activated macrophages (alveolar or peritoneal exudate) was assessed in culture against syngeneic melanoma cells. Our data demonstrate that under defined conditions the systemic administration of ADR does not interfere with the in situ activation of tumoricidal properties of murine macrophages after IV injection of liposomes containing a macrophage-activating agent.
Similar content being viewed by others
References
Cohen SA, Ehrke MJ, Ryoyama K, Mihich E (1982) Augmentation of the phagocytic activity of murine spleen cells by adriamycin. Immunopharmacology (in press)
Ehrke MJ, Cohen SA, Mihich E (1982a) Selective effects of adriamycin on murine host defense systems. Immunol Rev 65 (in press)
Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E (1982b) Kinetics of adriamycin induced immunomodulation: Dependence upon time of administration. Int J Immunopharmacol (in press)
Fidler IJ (1978) Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med Sci 14:177
Fidler IJ (1980) Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 208:1469
Fidler IJ (1981) In situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol 127:1719
Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78:1680
Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 42:496
Hart IR (1979) Selection and characterization of invasive variant of the B16 melanoma. Am J Pathol 97:587
Haskill JS (1981) Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res 41:3852
Hersh EM (1973) Modification of host defense mechanism. In: Holland JF, Frei E III (eds) Cancer medicine. Lea & Febiger, Philadelphia, p 681
Hersh EM (1974) Immunosuppressive agents. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. I. Springer, New York, p 577
Hisano G, Tominaga K, Yata K, Tsubura E (1978) Effect of antineoplastic agents, corticosteroids and antibiotics on murine T and B lymphocytes. Chemotherapy (Tokyo) 26:830
Mantovani A, Vecchi A, Tagliabue A, Spreafico F (1976) The effects of adriamycin and daunomycin on antitumoral immune effector mechanisms in an allogeneic system. Eur J Cancer 12:371
Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F (1979) Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. JNCI 63:61
Mihich E (1971) Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. In: Hall TC (ed) Prediction of response in cancer chemotherapy and immunity. US Government Printing Office, p 90 (NCI Monograph 34)
Mihich E (1975) Immunosuppression in cancer therapeutics. Proceedings of the first international symposium on cancer and transplantation. Transplant Proc 7:275
Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283:139
Poste G, Fidler IJ (1981) Stimulation of macrophage-mediated destruction of lung metastases by administration of immunomodulators encapsulated in liposomes. In: Nicolau C, Paraf A (eds) Study of drug activity and immunocompetent cell functions. Academic Press, New York, p 147
Raz A, Fogler WE, Fidler IJ (1979) The effects of experimental conditions on the expression of in vitro-mediated tumor cytotoxicity by murine macrophages. Cancer Immunol Immunother 7:157
Riccardi C, Puccetti P, Santoni A, Herberman R, Bonmassar E (1979) Adriamycin-induced antitumor responses in lethally irradiated mice. Immunopharmacology 1:211
Ryoyama K, Ehrke MJ, Mihich E (1981) Cell-cell interactions in the generation of ‘nonspecific’ suppressor cells in culture and its modification by adriamycin. In: Dubois JB, Serrou B, Rosenfeld C (eds) Immunopharmacologic effects of radiation therapy. Raven Press, New York, p 23
Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42:161
Schwartz HS, Grindey GB (1973) Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 33:1837
Schwartz H, Kanter P (1975) Cell interactions: Determinants of selective toxicity of adriamycin and daunorubicin. Cancer Chemother Rep 6:107
Stoychkov JN, Schultz RM, Chirigos MA, Pavlidis NA, Goldin A (1979) Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res 39:3014
Tomazic V, Ehrke MJ, Mihich E (1981) Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment. Cancer Res 41:3370
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hisano, G., Fidler, I.J. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol Immunother 14, 61–66 (1982). https://doi.org/10.1007/BF00200168
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00200168